Rafael Pharmaceuticals Crosses Enrollment of 150 Patients in Pivotal Phase 3 Trial (ARMADA 2000) of CPI-613® (Devimistat) for Relapsed or Refractory Acute Myeloid Leukemia (AML)

Frank Burrell
Scientific Storytelling

Joey Cohen
Medication Adherence

David Linetsky
Point-of-Care Marketing

Suma Ramadas, PhD
Medical Affairs

Paul Theisen
Patient Acquisition

Amy Giles
Increasing Engagement

Pat Purcell
Meeting Engagement

Brenda Snow
Authentic Patient Voice

Bud Bilanich
Success Coach

Matthew Durham
Omnidynamic Marketing

Stacey Gandler
Brand Nourishment

Matt Turner
Patient Affordability

Liz Kane
Impactful Strategy

Daniel Sontupe
Market Access